People

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The People

Governance grade: B+. A clean, fully UK Code-compliant board with a capable, externally credentialled executive team that has just executed a shareholder-friendly portfolio simplification — but the CEO and CFO are still early in their tenure and a long way from meeting Reckitt's (genuinely demanding) shareholding requirements, so alignment in absolute economic terms is still light.

The People Running This Company

Kris Licht — CEO single figure 2025 ($m)

7.81

Shannon Eisenhardt — CFO single figure 2025 ($m)

5.21

CEO shares owned outright

58,584

▲ 200,000 Required

CFO shares owned outright

5,239

▲ 100,000 Required

No Results

The people in charge are unusually well-credentialled even by FTSE 100 standards. Darroch (ex-Sky) was hired specifically to stabilise the boardroom after the chaotic Narasimhan exit (2022), the Durante interim period and the post-Mead Johnson goodwill writedowns. Licht and Eisenhardt are both "operator" rather than "deal-doer" CFO/CEO profiles — Licht is a Reckitt insider promoted from running Health, and Eisenhardt brings Nike's brand-finance and consumer discipline rather than M&A pedigree. That fits the "no more big acquisitions, simplify the portfolio" strategic thesis the company is now executing.

The two consistent gaps to flag:

Tenure risk. Licht has been CEO for ~2.5 years; Eisenhardt for ~2 years. Reckitt has had four CEOs (Kapoor, Narasimhan, Durante interim, Licht) and two chairs (Sinclair, Darroch) in the last seven years. Continuity is improving but not yet earned.
No clinical / regulatory heavyweight on the board. For a company carrying Mead Johnson Nutrition (NEC infant-formula litigation), an OTC drug portfolio (Mucinex, Nurofen, Strepsils, Gaviscon) and a Suboxone settlement legacy, the absence of a former regulator or pharma R&D heavyweight is conspicuous. Verduin (ex-CTO Colgate) helps; Khan (Takeda) leaving in July 2025 hurt.

What They Get Paid

No Results

The 2025 single figure of $7.81m for the CEO is essentially flat versus $7.32m in 2024, and is driven by genuine pay-for-performance machinery — the 2025 Annual Performance Award paid out at 56% of maximum, and the 2023–2025 LTIP vested at 63% with NR coming in at the threshold (41% vesting), ROCE near top end (84%), TSR between median and upper quartile (60%), and Sustainability targets fully met. None of those four metrics paid maximum, which is what you want to see in a "real" pay programme.

The Remuneration Committee did make one judgement-call addition: a +7% adjustment of maximum to the bonus outcome to recognise the Essential Home divestment, the corporate restructuring, and "the very strong shareholder experience this year". Adjustments of this kind ("performance in the round") are exactly where UK rem committees can lose investor trust, but in this case it was disclosed up-front, sized modestly, and made after consulting investors representing >50% of the register. Not a red flag.

The CEO's $1.54m base salary is below the FTSE 30 lower decile of ~$1.71m. The Committee is phasing in an 8% increase for 2026 (4% workforce-aligned + 4% catch-up) and signalling another adjustment for 2027. Total package, even after the rise, sits below FTSE 30 lower decile for salary and below median for FMCG global peer group. The CEO pay ratio at 1:104 has fallen sharply from the 1:177 peak in 2020 and is reasonable for a $44bn-plus consumer staples business.

Pay design is genuinely UK-best-practice: 80% of CEO total pay is variable; one-third of every bonus is deferred into shares for three years; LTIP awards have a five-year combined performance + holding period; post-employment shareholding requirements run two years beyond exit. Auditor (KPMG) and remuneration consultant (Deloitte) are independent of management. The Committee chose **PwC for 2027** after a 2024 tender — KPMG remains the auditor through FY2026 to avoid disrupting the transformation programme.

Are They Aligned?

Ownership and control

No Results

There is no controlling shareholder, no founding family stake, no dual-class structure. Reckitt has been a pure free-float consumer staple since the 1999 Reckitt & Colman / Benckiser merger. The Reimann/JAB family, sometimes referenced in the company's heritage, has not been a material holder for years. Activist Eminence Capital (Ricky Sandler) disclosed a stake of >0.5% in May 2024 and is widely reported to have pushed for the very portfolio split that culminated in the December 2025 Essential Home divestment. The activist won — and the win was returned to shareholders.

Skin in the game

No Results

Skin-in-the-game score (1–10)

▲ 10 of 10

Reckitt's required shareholding of 200,000 shares for the CEO and 100,000 for the CFO is among the most demanding in the UK market — equivalent to roughly 1,027% of CEO salary and 709% of CFO salary on the Q4 2025 average price of $79.09, and nearly double the annual LTIP award. There is also a two-year post-employment holding requirement equal to ~50% of the in-role threshold. That is genuine alignment.

The catch is that neither executive is close to the requirement yet. Licht owns 58,584 shares outright (29% of the requirement); Eisenhardt owns 5,239 (5% of hers). Both have an eight-year window from appointment, and the deferred bonus and LTIP pipeline will close most of the gap mechanically — but for now, today's economic alignment is well below the headline target. We score skin-in-the-game 5/10: the framework is excellent, the absolute exposure is modest, and the trajectory is the right one.

Insider trading and capital allocation

Capital returns are the clearest evidence of alignment. Reckitt completed $1,184m of buyback in 2025 (FY2024: $1,664m), paid a 5% progressive ordinary dividend, and on 20 February 2026 paid a special dividend of 235p / share = $2.15bn funded by the Essential Home sale to Advent (combined with a 24-for-25 share consolidation to neutralise the share-count effect). That is roughly $5.1bn returned in 2025–early-2026 out of a market cap of ~$44bn — north of 11% of equity value handed back in 14 months. No insider buying or selling of any consequence has been reported on RNS during 2025; Simply Wall St flagged in October 2025 that "insiders have been buying lately," but volumes are immaterial.

There is no material dilution, no warrant overhang, and no related-party transactions disclosed in the 2025 governance report beyond ordinary-course employee share schemes. The auditor transition to PwC for 2027 was run as a competitive three-firm tender; the remuneration consultant (Deloitte) is independent and a member of the Remuneration Consultants Group code.

**The activist trade worked for everyone.** Eminence pushed for portfolio simplification in 2024; the board agreed; Essential Home was sold to Advent for an amount sufficient to fund a $2.15bn special dividend; the management team's variable pay is largely tied to ROCE, NR growth, TSR and sustainability — measures that will look better against a smaller, higher-margin Core Reckitt. The interests of activists, the board, management and long-only holders are unusually well-aligned for a transition year.

Board Quality

No Results

The board passes the basic UK Code tests easily: all ten non-executive directors are independent, the Chair was independent on appointment, the Audit, Remuneration, Compliance, Nomination and CRSEC committees are properly constituted, the 2025 review was externally facilitated by Clare Chalmers, and the FY2025 Annual Report explicitly states full compliance with the UK Corporate Governance Code 2024. Auditor independence is being refreshed via the PwC tender outcome; KPMG audit fees and effectiveness are reviewed annually.

What's strong:

FMCG and finance bench is unusually deep. Bonfield (Caterpillar/Cadbury/BMS), Della Valle (Vodafone CEO/CFO), Dawson (Mars 30y), Stock (Kimberly-Clark/ServiceMaster), Hays (Walmart), Madhavan (Bacardi) and Oschmann (Merck KGaA CEO) are all top-quartile operators in their domains.
No tenure block. Median NED tenure is ~3 years. Stock and Bonfield are the long-servers at 7–8 years and both move out of the independence window only after 9.

What's missing:

No former regulator or pharma-quality leader. With infant-formula NEC litigation (Mead Johnson) and historical Suboxone exposure (Indivior, settled 2019 for $1.4bn), Reckitt's board would benefit from a former FDA / MHRA / EMA / DOJ figure. Verduin (Colgate R&D) and Oschmann (Merck KGaA) help, but neither sits squarely in the regulator-and-litigation lane.
2026 churn. Della Valle and Madhavan are stepping down at the May 2026 AGM. Two senior NEDs in one year is manageable but the Nomination Committee will need to refill quickly to keep Audit and Remuneration committees fully populated.

The Verdict

Governance grade

B+

**What's working.** Independent UK Code-compliant board with FMCG-deep bench. Externally evaluated 2025. Auditor refresh in motion (PwC from 2027). Pay programme is well designed — 80%+ variable, deferred, with a five-year combined performance + holding window. The activist trade was constructive: Eminence pushed for the Essential Home split, the board executed, and shareholders received a $2.15bn special dividend plus $1.18bn buyback in 2025.

**Real concerns.** (1) The CEO and CFO own 29% and 5% of their (very demanding) shareholding requirements respectively — alignment is mechanical and forward-looking, not yet economic. (2) Reckitt has had four CEOs in seven years; Licht's continuity track record is short. (3) The Mead Johnson NEC litigation tail and the Middle East under-reporting investigation in 2024 are reminders that compliance risk is recurring at this group, and there is no former regulator or quality-systems heavyweight on the board. (4) Two senior NEDs (Della Valle, Madhavan) are leaving at the 2026 AGM, requiring rapid replacement.

Most likely upgrade trigger: Licht and Eisenhardt cross 50% of their shareholding requirements (mechanically should happen by 2027–2028 via deferred bonus + LTIP vesting); Mead Johnson NEC litigation resolves at a containable cost; the 2026 NED replacements include a regulatory or pharma-quality figure.

Most likely downgrade trigger: A material adverse Mead Johnson NEC verdict; a second compliance investigation (analogous to Middle East 2024); or any sign that the +7% "performance-in-the-round" bonus adjustment becomes a recurring practice.

Generated Apr 28, 2026 06:29 UTC